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Twenty-seven (66%) patients were taking antithrombotics (20 antiplatelets and 7 anticoagulants). In patients with probable CAA, the proportion was 81% (11 antiplatelets 2 anticoagulants). Fourteen (34%) patients were treated previously with statins. Eight patients were taking selective serotonin reuptake inhibitors (3/9 with RCVS/posterior reversible encephalopathy syndrome). One patient with RCVS used illicit drugs, and 2 patients used licit sympathomimetics.
Clinical Features
Most presented with a combination of symptoms (Table II  in 
Radiology Findings
Thirty-nine patients (95%) initially underwent computed tomographic neuroimaging. The remaining 2 patients underwent MRI. Subsequently, MRI was performed on 33 patients. In total, 22 patients (54%) received gradient echo or susceptibility weighted imaging sequences. Vessel imaging was performed in 34 patients. Findings are detailed in Table III 
Pathogenesis
Probable CAA was the commonest cause of cSAH (16/41 cases; Table; Figure) . The second commonest cause was RCVS (7/41). Five definite cases 6 had normal follow-up angiography, and 2 probable cases had classical thunderclap headache presentation, 1 case after intravenous amphetamines, with symptom resolution after nimodipine without immunosuppression. Tight atherosclerotic stenosis (n=4), cerebral venous sinus thrombosis (n=4), and posterior reversible encephalopathy syndrome (n=2) were also evident in multiple cases. All patients with CAA were ≥65 years old. All patients with RCVS and posterior reversible encephalopathy syndrome were <60 years old. Cerebral venous sinus thrombosis and stenosis-related cSAH straddled this age dichotomy. Twenty patients (49%, all with TFNS) were initially misdiagnosed with transient ischemic attack. In all, preexisting antithrombotic therapy was inappropriately escalated or commenced. In 14 (34%) patients, subsequent imaging suggested worsening cSAH.
Discussion
To our knowledge, we report the clinical association and causes of cSAH in the largest mixed pathogenesis case series. We give the first estimate of population incidence. The overall conclusions of our study mirror previous reports. 1-3 cSAH represents a significant SAH subcategory (6% versus 7% reported previously). 3 CAA is the commonest cause in patients >60 years old, and RCVS in those <60 years old. Presentations are distinct, the former with slowly evolving TFNS, the latter usually with thunderclap headache (but sometimes rapid onset focal neurological deficits or seizures).
In contrast with the series of Kumar et al, 1 our commonest presenting complaint was TFNS (66%) not headache (62%), perhaps reflecting a lower RCVS proportion and higher median age. In addition to CAA and RCVS, our study also documented multiple cases with posterior reversible encephalopathy syndrome, cerebral venous sinus thrombosis, and parent vessel stenosis (Figure) .
Most patients presenting with TFNS (22 of 27) were >60 years old. Sixteen patients had probable CAA. The remaining 6 patients were possible CAA because they were incompletely investigated. The central sulcus seems to be an area particularly prone to cSAH-induced TFNS. We confirmed previous reports that TFNS are commonly misdiagnosed as transient ischemic attacks. 8 This misdiagnosis (particular as crescendo transient ischemic attacks) may lead to iatrogenic bleeding risk and (if epilepsy is misdiagnosed) unwarranted licensing restrictions.
Our study demonstrated a minimum population incidence of 5.1 per million/year. This is most likely an underestimate because of several study limitations. First, our review was retrospective, lacking characteristics of an ideal incidence study. 9 Second, in several cases, cSAH was subtle and initially missed, suggesting many cases of cSAH may remain undiagnosed. Finally, only publicly admitted cases primarily coded as SAH with available electronic records were reviewed. Coding is often inaccurate; 6% were not actually SAH; and only 4/9 patients with cSAH seen by the authors in this time frame were coded correctly. Cases (especially of CAA-related TFNS) may not be investigated or not seek medical attention at all. Therefore, true cSAH incidence is probably at least double our estimate. An ideal unbiased cSAH incidence study would require comprehensive, prospective, expert, blinded neuroimaging review of a large heavily investigated population during several years.
In conclusion, nontraumatic cSAH occurs relatively commonly. CAA and RCVS are most frequent causes. Increased awareness will prevent misdiagnosis as transient ischemic attack (or seizures) and prevent potentially harmful treatment.
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